Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)—A Potential New Standard of Care

The treatment paradigm for metastatic castrate-sensitive prostate cancer (mCSPC) has evolved rapidly in the past decade with the approval of several life-prolonging therapies including docetaxel chemotherapy and multiple androgen receptor pathway inhibitors (ARPI) in combination with androgen depriv...

Descripción completa

Detalles Bibliográficos
Autores principales: Mittal, Abhenil, Sridhar, Srikala S., Ong, Michael, Jiang, Di Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136811/
https://www.ncbi.nlm.nih.gov/pubmed/37185445
http://dx.doi.org/10.3390/curroncol30040332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136811/
https://www.ncbi.nlm.nih.gov/pubmed/37185445
http://dx.doi.org/10.3390/curroncol30040332

Ejemplares similares